MoonLake Immunotherapeutics Financial Statements
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.82+0.24 (+2.27%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MoonLake Immunotherapeutics revenue and earnings
MoonLake Immunotherapeutics reported a net loss of $227.3 million, compared with a loss of $118.9 million a year earlier. Diluted earnings per share came in at -$3.53.
Summary generated from market data by MetaCap's automated system. Methodology
MoonLake Immunotherapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Operating Expenses | 244.83M | 143.09M | 54.12M | 65.06M | — |
| Research & Development | 202.86M | 112.77M | 31.80M | 42.05M | — |
| Operating Income | -244.83M | -143.09M | -54.12M | -65.06M | -4.57M |
| Interest Expense | 7.25M | 0 | 0 | — | — |
| Other Income (Expense) | 22.37M | 22.13M | 10.14M | 591.73K | 27.69K |
| Pretax Income | -229.71M | -120.96M | -43.98M | -64.47M | — |
| Income Tax | 611.00K | 282.00K | 94.00K | 36.37K | — |
| Net Income | -227.32M | -118.94M | -36.01M | -49.97M | -4.54M |
| Net Income growth (YoY) | — | — | — | — | — |
| EPS (Basic) | -3.53 | -1.89 | -0.73 | -1.70 | -0.31 |
| EPS (Diluted) | -3.53 | -1.89 | -0.73 | -1.70 | -0.31 |
| Shares Outstanding (Basic) | 64.46M | 62.87M | 49.12M | 29.36M | 11.93M |
| Shares Outstanding (Diluted) | 64.46M | 62.87M | 49.12M | 29.36M | 360.00M |
| EBITDA | -242.22M | -141.71M | -53.75M | -64.90M | — |
This table shows 5 annual periods of MoonLake Immunotherapeutics's income statement, from FY 2025 back to FY 2021, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MLTX's reporting calendar. What is a income statement?